UBS initiated coverage of Sight Sciences (SGHT) with a Buy rating and $5.50 price target After a tough 2024, 2025 represents a “foundational building year” in which the company’s key growth driver will shift away from the legacy Omni surgical solution to treat glaucoma and to the TearCare dry eye solution, the analyst tells investors in a research note. The firm says TearCare addresses more than 11M patients with meibomian gland disease with an addressable market of $2.5B.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences assumed with an Equal Weight at Morgan Stanley
- Sight Sciences price target lowered to $5 from $7 at Morgan Stanley
- Sight Sciences price target lowered to $5.50 from $6 at Piper Sandler
- Sight Sciences Reports Modest Growth and Optimistic Outlook
- Sight Sciences backs FY24 revenue view, sees operating expenses down 4%-6%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
